The first two authors contributed equally to this work.
Defective tumor necrosis factor release from Crohn's disease macrophages in response to toll-like receptor activation: Relationship to phenotype and genome-wide association susceptibility loci†
Article first published online: 20 MAR 2012
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 11, pages 2120–2127, November 2012
How to Cite
Sewell, G. W., Rahman, F. Z., Levine, A. P., Jostins, L., Smith, P. J., Walker, A. P., Bloom, S. L., Segal, A. W. and Smith, A. M. (2012), Defective tumor necrosis factor release from Crohn's disease macrophages in response to toll-like receptor activation: Relationship to phenotype and genome-wide association susceptibility loci. Inflamm Bowel Dis, 18: 2120–2127. doi: 10.1002/ibd.22952
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
- Issue published online: 15 OCT 2012
- Article first published online: 20 MAR 2012
- Manuscript Accepted: 17 FEB 2012
- Manuscript Received: 10 FEB 2012
- Wellcome Trust. Grant Number: (grant GHACB)
- National Association of Colitis and Crohn's disease
- genetic polymorphisms;
- Crohn's disease
Recent work provides evidence of a failure of acute inflammation in Crohn's disease (CD), and suggests that the primary defect operates at the level of the macrophage and cytokine release. Here we extend the characterization of the innate immune defect in CD by investigating the macrophage response to Toll-like receptor (TLR) agonists and assess potential links between genome-wide association study (GWAS) susceptibility loci, disease phenotype, and therapeutic regimens on tumor necrosis factor α (TNF) release.
Peripheral blood-derived macrophages were cultured from control subjects and patients with CD, stimulated with TLR ligands, and the release of TNF measured. Genomic DNA was purified from blood and genotyped for 34 single nucleotide polymorphisms (SNPs) identified as being associated with CD by GWAS.
All stimuli resulted in a reduction (32%–48%) in TNF release from macrophages derived from CD patients (n = 28–101) compared to those from healthy control (HC) subjects. All phenotypes demonstrated impaired TNF release, with the greatest defect in patients with colonic disease. There was no detectable relationship between the level of TNF released and the presence of GWAS susceptibility loci in CD patients. Reduced TNF levels were not influenced by age, gender, or use of aminosalicylate (5-ASA) medication.
This study supports the hypothesis of defective proinflammatory cytokine secretion and an innate immunodeficiency in CD. Abnormal TNF secretion is evident downstream of multiple TLRs, affects all disease phenotypes, and is unrelated to 34 polymorphisms associated with CD by GWAS. (Inflamm Bowel Dis 2012;)